Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COPA-R-CHOP in previously untreated DLBCL
2024-517166-42-00Phase 2Completed
- Sponsor
- Universitätsklinikum Münster
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of copanlisib in diffuse large B-cell lymphoma (DLBCL), large-cell lymphoma and follicular lymphoma (FL), sponsored by Universitätsklinikum Münster. Primary endpoints: Recommended phase 2 dose (RP2D) of copanlisib in combination with R-CHOP and 2-year progression-free survival. Started Sep 2024; status: completed.
02
Drugs
copanlisib
03
Conditions
diffuse large B-cell lymphoma (DLBCL)large-cell lymphomafollicular lymphoma (FL)
Beyond the preview
Go deeper on 2024-517166-42-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517166-42-00.